Expand NUVL Menu
NUVL MENU

NUVL Latest Press Releases

-- April 7, 2026 --

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC PRNewswire 6:30 AM

-- March 17, 2026 --

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 PRNewswire 5:16 PM

-- February 26, 2026 --

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results PRNewswire 6:30 AM

-- February 5, 2026 --

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 PRNewswire 6:30 AM

-- January 12, 2026 --

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones PRNewswire 6:30 AM

-- December 22, 2025 --

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 6:30 AM

-- December 10, 2025 --

Nuvalent Appoints Ron Squarer to Board of Directors PRNewswire 4:01 PM

-- November 26, 2025 --

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference PRNewswire 6:30 AM

-- November 24, 2025 --

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders PRNewswire 4:01 PM

-- November 19, 2025 --

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC PRNewswire 4:20 PM

-- November 18, 2025 --

Nuvalent Announces Pricing of Public Offering of Common Stock PRNewswire 11:50 PM

-- November 17, 2025 --

Nuvalent Announces Public Offering of Common Stock PRNewswire 4:01 PM
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC PRNewswire 6:30 AM
Market Data Delayed 15 Minutes